Spencer F. Simon is a partner in Willkie’s Intellectual Property Department. Spencer’s practice focuses primarily on the representation of technology-intensive companies in all aspects of intellectual property, corporate and other commercial transactions, and data protection and cybersecurity matters. His practice covers a broad spectrum of technologies, including software, fintech, pharmaceutical, biotechnology, medical devices, semiconductor and telecommunications.


  • Panelist, “Structuring IP Provisions in Asset Purchase Agreements,” Strafford Publications webinar (May 2016)
  • Panelist, “Contractual Provisions to Mitigate Risk,” Executive Enterprise Institute’s Best Practices in Due Diligence (May 2013)
  • Presentation, “Intellectual Property Due Diligence: Select IP Considerations in M&A,” Executive Enterprise Institute’s Advanced Due Diligence Practices (May 2012) 
  • ACE Limited in its $29.5 billion acquisition of The Chubb Corporation
  • Ally Financial in its $4.2 billion sale of its operations in Europe and Latin America to General Motors Financial and its $4.1 billion sale of its Canadian auto finance business to the Royal Bank of Canada
  • American Family Insurance Group in the sale of a majority stake in the attorney-in-fact of Trusted Resource Underwriters Exchange to funds managed by Gallatin Point Capital
  • American International Group in its sale of AIG Advisor Group to Lightyear Capital and PSP Investments, sale of United Guaranty Corporation to Arch Capital Group; and its partnership with Hamilton Insurance Group and affiliates of Two Sigma Investments to establish a technology-enabled, customer-centric insurance platform for the small to medium-sized enterprise market
  • Amgen in its $10.5 billion acquisition of Onyx Pharmaceuticals
  • AT&T in its $67 billion acquisition of DIRECTV, $1.2 billion acquisition of Leap Wireless International and $2 billion cash sale of its incumbent local exchange operations in Connecticut to Frontier Communications
  • Bayer in its $14.2 billion acquisition of the consumer care business of Merck and pending $66 billion acquisition of Monsanto
  • BBA Aviation in its $2.1 billion acquisition of Landmark Aviation
  • Bright House Networks in its three-way combination with Charter Communications and Time Warner Cable, to create an $80 billion cable company
  • Cablevision Systems in its $17.7 billion acquisition by Altice and its $1.6 billion sale of Bresnan Broadband Holdings
  • Collective Brands in its $2 billion sale to a consortium including Wolverine Worldwide, Blum Capital Partners and Golden Gate Capital
  • CVS Health in its $2.1 billion acquisition of Coram from Apria and $12.7 billion acquisition of Omnicare
  • Cytec Industries in its $6.4 billion merger with Solvay
  • DISH Network in its pending agreement with EchoStar pursuant to which DISH is to acquire certain hardware, software and over-the-top assets in exchange for DISH’s interests in Hughes Retail Group
  • Dyax in its $5.9 billion acquisition by Shire
  • Endo International in its $2.6 billion acquisition of Auxilium Pharmaceuticals
  • Goldman Sachs Principal Investment Area in multiple transactions
  • Idenix Pharmaceuticals in its $3.9 billion acquisition by Merck
  • Kodak in its worldwide IP-intensive restructuring, including the $527 million sale of its digital imaging patent portfolio (1,100 patents) to Intellectual Ventures and a series of associated patent licensing transactions with Apple, Google, Microsoft, Facebook, Samsung, Amazon, Adobe, Fujifilm, HTC, Huawei, Research in Motion and Shutterfly
  • Kraft Foods Group in its $55 billion merger with H.J. Heinz Company to create The Kraft Heinz Company
  • LabCorp in its $6.1 billion acquisition of Covance
  • The Priceline Group in its $2.6 billion acquisition of OpenTable and $1.8 billion acquisition of KAYAK Software
  • Royal Bank of Canada in its $5.4 billion acquisition of City National
  • Stryker Corporation in its $2.8 billion pending acquisition of Sage Products from Madison Dearborn Partners
  • Synageva BioPharma in its $8.7 billion acquisition by Alexion Pharmaceuticals
  • Terumo Corporation in its $1.12 billion acquisition of certain vascular closure product lines and access technologies from Abbott Laboratories and St. Jude Medical
  • Teva Pharmaceutical Industries in its $40.5 billion acquisition of Allergan Generics
  • UnitedHealth Group in the $12.8 billion combination of subsidiary OptumRx and Catamaran Corporation
  • Valeant Pharmaceuticals in its $15.8 billion acquisition of Salix Pharmaceuticals; $56 billion unsolicited merger proposal and tender offer for Allergan, later terminated; and $1.4 billion sale of aesthetic products to Galderma
  • Veritas Capital in its $1.25 billion acquisition of the health analytics business of Thomson Reuters
  • ZF Friedrichshafen in its $12.4 billion acquisition of TRW Automotive Holdings

* Spencer advised on these matters prior to joining Willkie.



University of California at Berkeley, School of Law, J.D., 1999 University of California, Los Angeles, B.A., 1994

Bar Admissions

New York, 2014 California, 2000